Abstract
A staphylolytic fusion protein (chimeric enzyme K-L) was created, harboring three unique lytic activities composed of the LysK CHAP endopeptidase, and amidase domains, and the lysostaphin glycyl-glycine endopeptidase domain. To assess the potential of possible therapeutic applications, the kinetic behavior of chimeric enzyme K-L was investigated. As a protein antimicrobial, with potential antigenic properties, the biophysical effect of including chimeric enzyme K-L in anionic polymer matrices that might help reduce the immunogenicity of the enzyme was tested. Chimeric enzyme K-L reveals a high lytic activity under the following optimal (opt) conditions: pHopt 6.0–10.0, topt 20–30 °C, NaClopt 400–800 mM. At the working temperature of 37 °C, chimeric enzyme K-L is inactivated by a monomolecular mechanism and possesses a high half-inactivation time of 12.7 ± 3.0 h. At storage temperatures of 22 and 4 °C, a complex mechanism (combination of monomolecular and bimolecular mechanisms) is involved in the chimeric enzyme K-L inactivation. The optimal storage conditions under which the enzyme retains 100 % activity after 140 days of incubation (4 °C, the enzyme concentration of 0.8 mg/mL, pH 6.0 or 7.5) were established. Chimeric enzyme K-L is included in complexes with block-copolymers of poly-l-glutamic acid and polyethylene glycol, while the enzyme activity and stability are retained, thus suggesting methods to improve the application of this fusion as an effective antimicrobial agent.
Similar content being viewed by others
References
Nelson, D. C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D. G., Dong, S., & Donovan, D. M. (2012). Endolysins as antimicrobials. Advances in Virus Research, 83, 299–365.
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012). Bacteriophage endolysins as novel antimicrobials. Future Microbiology, 7(10), 1147–1171.
Yang, H., Yu, J., & Wei, H. (2014). Engineered bacteriophage lysins as novel anti-infectives. Frontiers in Microbiology, 5, 542.
Becker, S. C., Foster-Frey, J., & Donovan, D. M. (2008). The phage K lytic enzyme LysK and Lysostaphin act synergistically to kill MRSA. FEMS Microbiology Letters, 187(2), 185–191.
Flaherty, S. O., Coffey, A., Meaney, W., Fitzgerald, G. F., & Ross, R. P. (2005). The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. Journal of Bacteriology, 187(20), 7161–7164.
Horgan, M., Flynn, G., & Cooney, J. (2009). The phage lysin, LysK, can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Applied and Environmental Microbiology, 75(3), 872–874.
Patron, R. L., Climo, M. W., Coldstein, B. P., & Archer, G. L. (1999). Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrobial Agents and Chemotherapy, 43(7), 1754–1755.
Browder, H. P., Zygmunt, W. A., Young, G. R., & Tavormina, P. A. (1965). Lysostaphin: enzymatic mode of action. Biochemical and Biophysical Research Communications, 19(3), 383–389.
Fischetti, V. A. (2005). Bacteriophage lytic enzymes: novel anti-infectives. Trends in Microbiology, 13(10), 491–496.
Donovan, D. M., & Becker, S. C. (2010). Patent US 20100158886 A1. Beltsville: Beltsville Agricultural Research Center, USDA.
Donovan, D. M., Becker, S. C., Dong, S., Baker, J. R., Foster-Frey, J., & Pritchard, D. G. (2009). Peptidoglycan hydrolase enzyme fusions for treating multi-drug resistant pathogens. Biotech International, 21, 6–10.
Rodríguez-Rubio, L., Martínez, B., Rodríguez, A., Donovan, D., Götz, F., & García, P. (2013). The phage lytic proteins from the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 display multiple active catalytic domains and do not trigger staphylococcal resistance. PLoS ONE, 8(5), e64671.
Severian, D., & Valentin, P. (2013). Polymeric biomaterials: medicinal and pharmaceutical applications. Volume 2. NY: Taylor and Francis Group.
Cleland, J. L., Powell, M. F., & Shire, S. J. (1993). The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Critical Reviews in Therapeutic Drug Carrier Systems, 10, 307–377.
McGowan, S., Buckle, A. M., Mitchell, M. S., Hoopes, J. T., Gallagher, D. T., Heselpoth, R. D., Shen, Y., Reboul, C. F., Law, R. H. P., Fischetti, V. A., Whisstock, J. C., & Nelson, D. C. (2012). X-ray crystal structure of the streptococcal specific phage lysin PlyC. Proceedings of the National Academy of Sciences of the United States of America, 109, 12752–12757.
Miao, J., Pangule, R. C., Paskaleva, E. E., Hwang, E. E., Kane, R. S., Linhardt, R. J., & Dordick, J. S. (2011). Lysostaphin-functionalized cellulose fibers with antistaphylococcal activity for wound healing applications. Biomaterials, 32(36), 9557–9567.
Filatova, L. Y., Becker, S. C., Donovan, D. M., Gladilin, A. K., & Klyachko, N. L. (2010). LysK, the enzyme lysing Staphylococcus aureus cells: specific kinetic features and approaches towards stabilization. Biochimie, 92(5), 507–513.
Filatova, L. Y., Donovan, D. M., Becker, S. C., Lebedev, D. N., Priyma, A. D., Koudriachova, H. V., Kabanov, A. V., & Klyachko, N. L. (2013). Physicochemical characterization of the staphylolytic LysK enzyme in complexes with polycationic polymers as a potent antimicrobial. Biochimie, 95(9), 1689–1696.
Bregg, R. C. (2006). New Frontiers in Polymer Research. New York: Nova science publishers.
Kadajji, V. G., & Betageri, V. G. (2011). Water soluble polymers for pharmaceutical applications. Polymers, 3, 1972–2009.
Damodaran, V. D. (2010). Protein PEGylation: an overview of chemistry and process considerations. European Pharmaceutical Review, 15(1), 18–26.
Filatova, L. Y., Donovan, D. M., Foster-Frey, J., Pugachev, V. G., Dmitrieva, N. F., Chubar, T. A., Klyachko, N. L., & Kabanov, A. V. (2015). Bacteriophage phi11 lysin: physicochemical characterization and comparison with phage phi80α lysin. Enzyme and Microbial Technology, 7374C, 51–58.
Levanov, A. V., & Antipenko, E. E. (2006). Introduction to chemical kinetics (1st ed.). Moscow: Moscow University Press.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227(5262), 680–685.
Surovtsev, V. I., Borzenkov, V. M., Fedorov, T. V., & Smotrov, O. I. (2007). Ionogenic groups in the active site of lysostaphin. Kinetic and thermodynamic data compared with X-ray crystallographic data. Biochemistry (Moscow), 72(9), 989–993.
Iversen, O.-J., & Grov, A. (1973). Studies on lysostaphin. Separation and characterization of three enzymes. European Journal of Biochemistry, 38(2), 293–300.
Wang W., & Roberts, C. Aggregation of therapeutic proteins. New York: John Wiley & Sons.
Nakai S., & Modler, H. Food proteins: properties and characterization. New York: John Wiley & Sons.
Lavasanifar, A., Samuel, J., & Kwon, G. S. (2002). Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Advanced Drug Delivery Reviews, 54(2), 169–190.
Acknowledgments
The study was carried out by SkolTech N 182-MRA and was supported by BARD grant no. IS-4573-12R/58-1265-2-132.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Fig. S1
(DOCX 22 kb)
Rights and permissions
About this article
Cite this article
Filatova, L.Y., Donovan, D.M., Ishnazarova, N.T. et al. A Chimeric LysK-Lysostaphin Fusion Enzyme Lysing Staphylococcus aureus Cells: a Study of Both Kinetics of Inactivation and Specifics of Interaction with Anionic Polymers. Appl Biochem Biotechnol 180, 544–557 (2016). https://doi.org/10.1007/s12010-016-2115-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-016-2115-7